MedTrace Logo

A Trial of Oral VRB-103 Alone or in Combination With Oral Ecnoglutide (VRB-101) in Participants With Obesity or Overweight

NCT07628127 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 336

Last updated 2026-08-11

No results posted yet for this study

Summary

The primary objective is to evaluate the safety and tolerability of VRB-103 tablets administered as monotherapy or VRB-103 tablets administered in combination with oral ecnoglutide tablets (VRB-101 tablets) in a single-dose regimen or in a multiple dose regimen.

Conditions

Interventions

OTHER

Placebo

Placebo tablets will be administered orally.

DRUG

VRB-101

VRB-101 tablets will be administered orally.

DRUG

VRB-103

VRB-103 tablets will be administered orally.

Sponsors & Collaborators

  • Verdiva Bio Dev Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-07-06
Primary Completion
2028-03-31
Completion
2028-03-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07628127 on ClinicalTrials.gov